NK042 / Shanghai NK CellTech - LARVOL DELTA

An Open-Label, Single-Arm Clinical Study to Evaluate the Safety and Preliminary Efficacy of CD20 Monoclonal Antibody Combined With NK042 Cell Injection in the Treatment of Multiple Sclerosis (MS). (clinicaltrials.gov) - P1 | N=20 | Not yet recruiting | Sponsor: The Affiliated Hospital of Xuzhou Medical University

New P1 trial • CNS Disorders • Multiple Sclerosis

NKSOLID: A Phase I Study of NK042 Cell Injection in Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=76 | Recruiting | Sponsor: Shanghai NK Cell Technology Co., LTD | Trial completion date: Dec 2026 ➔ Jun 2027 | Trial primary completion date: Jun 2026 ➔ Dec 2026

Trial completion date • Trial primary completion date • Oncology • Solid Tumor

NK010 or NK042 in Combination with Rituximab for Refractory Systemic Lupus Erythematosus/lupus Nephritis (clinicaltrials.gov) - P1 | N=18 | Recruiting | Sponsor: Guangdong Provincial People's Hospital | Not yet recruiting ➔ Recruiting

Enrollment open • Glomerulonephritis • Immunology • Inflammatory Arthritis • Lupus • Lupus Nephritis • Nephrology • Systemic Lupus Erythematosus

Enkasai’s NK042 cell injection has received implicit approval for clinical trials from China’s NMPA [Google translation] (PRNewswire-Asia) - "On May 22, 2024, the gene-modified natural killer cell injection (product code NK042 ) independently developed by Shanghai Enka Cell Technology Co., Ltd. (Enkasai Pharmaceutical) was approved by the Drug Evaluation Center of the China National Medical Products Administration for clinical trials...NK042 is a universal gene-modified NK cell injection derived from allogeneic peripheral blood, which has the potential to treat solid tumors, blood tumors and non-tumor diseases. The indications for this Phase I clinical trial are various solid tumors."

New P1 trial • Gynecologic Cancers • Oncology • Solid Tumor